AstraZeneca Trixeo Wins EU Approval for Asthma Treatment
Cambridge, United Kingdom, September 23, 2026 AstraZeneca has announced that Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has received European Commission...
Respiratory Medicine
Advertisement
Roivant and Pulmovant to Unveil Topline Mosliciguat Results in PH-ILD
Basel, Switzerland / London, UK / New York, NY — September 6, 2026 Roivant and Pulmovant announced that topline...
GSK Files EU Submission for Lower-Carbon Ventolin
London, UK, September 7, 2026 GSK plc has submitted a regulatory application in the European Union for a next-generation,...
GSK Accelerates R&D After Strong Q2 2026 Performance
LONDON, July 30, 2026 GSK has reported strong Q2 2026 financial results, driven by continued growth across its Specialty...
Sino Biopharm Secures $2.1B TQC3721 AstraZeneca Agreement
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
Advertisements
Nuvaira Develops First Targeted Therapy for COPD Phenotype
MINNEAPOLIS, Minnesota, July 1, 2026 Nuvaira, Inc. has announced the first patient treated in the pivotal AIRFLOW-4 clinical trial...
Rein Therapeutics Expands Phase 2 RENEW Trial into the UK
AUSTIN, Texas, June 11, 2026 Rein Therapeutics, Inc. (NASDAQ: RNTX) announced the expansion of its ongoing Phase 2 RENEW...
Altesa’s Vapendavir Shows Promise in Preventing COPD Flares
WASHINGTON, D.C., June 5, 2026 Altesa BioSciences has unveiled encouraging new Phase 2 clinical findings demonstrating that vapendavir, its...
Achieve Life Sciences Reports 52-Week Safety Data for Cytisinicline
SEATTLE and VANCOUVER, British Columbia, May 19, 2026 Achieve Life Sciences announced positive long-term safety data from the ORCA-OL...
Oorja Bio Reports Positive Phase 1 Data for ORJ-001 in IPF
HOUSTON, Texas, May 19, 2026 Oorja Bio announced positive first-in-human Phase 1 clinical data for ORJ-001, a first-in-class peptide...
Advertisement
